Retatrutide 30mg Vial

What Retatrutide does: Retatrutide is the most advanced weight-loss and metabolic peptide ever created. It's researched for the largest fat loss and body weight reduction ever recorded in clinical trials (up to 28.7%), lowering blood sugar, reducing appetite, and improving overall metabolic health — surpassing everything before it including tirzepatide and semaglutide.

PEPTIVA RETATRUTIDE 30MG VIAL contains 30mg of high-purity lyophilised retatrutide (LY3437943) — the world's first investigational triple-agonist peptide simultaneously activating GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly and currently in the TRIUMPH Phase 3 clinical programme, retatrutide has demonstrated unprecedented efficacy — with TRIUMPH-4 reporting up to 28.7% body weight reduction at 48 weeks (the largest weight loss ever recorded in a Phase 3 obesity trial). The triple-agonist mechanism leverages: (1) GLP-1 receptor activation for glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite regulation; (2) GIP receptor activation for enhanced insulin secretion and adipose tissue modulation; and (3) glucagon receptor activation for increased energy expenditure, hepatic glucose output regulation, and lipolysis stimulation. Together these pathways produce metabolic effects beyond any dual-agonist or single-agonist GLP-1 compound.